May 2017 issue

April 1, 2017 issue

March 2017 issue

February 2017 issue

January 2017 issue













Each issue will include an editorial on a topic that is important for the profession of pharmacy, as well as a review of a new drug that includes a comparison of the new drug with previously marketed drugs that are most similar in activity, and a New Drug Comparison Rating (NDCR) for the new drug. Read on for this month's issue.

December 2010 Issue
Appreciation and Anticipation
New therapeutic agents marketed in the United States in 2010
Indexes for Volume 1, 2006 through Volume 5, 2010

Click Here to download PDF format

Appreciation and Anticipation
To Top]

With this issue we mark the completion of the fifth year of publication of The Pharmacist Activist (all issues are available on the website, www.pharmacistactivist.com. My motivation to continue publishing this newsletter is derived from the positive responses I receive from many readers. I very much appreciate these responses, the vast majority of which are supportive of the opinions I voice in editorials and the ratings I provide for new drugs. However, I also welcome the responses that do not agree with my opinions because the greater awareness of differing perspectives regarding challenging issues may bring us closer to solutions and courses of action that will better serve our patients, communities, and profession. If you know pharmacists and pharmacy students who are not presently receiving The Pharmacist Activist, please encourage them to go on the website and sign up to receive it. As an alternative, you could submit the necessary information for them and then inform them that you have provided them with a gift of a lifetime subscription to The Pharmacist Activist.

NEWS-Line Publishing produces this newsletter at its cost, and I wish to express my personal appreciation to Jeff Zajac, Joe Monte, John Buck, Chris Polli, and Patrick Polli for their expertise and enthusiasm in publishing The Pharmacist Activist. Although I do not receive compensation for my responsibility as author/editor, there are considerable expenses in producing this newsletter. I wish to express my deep appreciation to a friend who has provided financial support because of his commitment to advance the profession of pharmacy through stimulation of discussion/debate on important issues and challenges, as well as objective information on new drugs.

Many of the topics considered in the editorials in The Pharmacist Activist represent problems that may seem impossible to resolve. Some of the problems that have continued over a period of years have more recently been joined by the challenges of health insurance reform legislation and the tightening of the job market for pharmacists. However, the value of the role of our profession and the expertise and services of pharmacists makes it imperative that we not give up in our efforts to convert problems into opportunities and, indeed, that we strengthen our efforts and our activism in achieving positive outcomes. One of the reasons for which I continue to be highly enthusiastic about the future of our profession and can strongly encourage young people to consider pharmacy as a career is that, in my long experience, there has not been another time when there has been a greater need for the expertise of pharmacists. Much remains to be done in obtaining respect, utilization, and compensation for our expertise but, for the sake of our patients and communities, as well as for our profession, we must do it! Therefore, it is with anticipation of greater progress toward this goal that I look forward to what we can accomplish in 2011.

Best wishes for a healthy and enjoyable new year!

Daniel A. Hussar

New therapeutic agents marketed in the United States in 2010 [To Top]

Click here to view New therapeutic agents marketed in the United States in 2010

Indexes for Volume 1, 2006
through Volume 5, 2010

[To Top]

Index for
Volume 1, 2006

January 2006 (No. 1)
• Feature - The Sleeping Giant
• Editor's Note
• New Drug Review: Pregabalin (Lyrica)

February 2006 (No. 2)
• Feature - The Medicare Prescription Benefit??
• Letter to Senator Rick Santorum
• New Drug Review: Eszopiclone (Lunesta)

March 2006 (No. 3)
• Feature - A Tribute and a Warning
• Letter to President Bush
• New Drug Review: Ibandronate sodium (Boniva)

April 2006 (No. 4)
• Feature - Independent Pharmacists–The Front Line of our Profession
• Distinguished Leadership
• New Drug Review: Lubiprostone (Amitiza)

May 2006 (No. 5)
• Feature - The Justice Department Should Not Settle with MEDCO!
• Inspiration
• New Drug Review: Varenicline tartrate (Chantix)

June 2006 (No. 6)
• Feature - Shame on CVS!
• Target Provides some Good Examples
• New Drug Review: Insulin detemir (Levemir)

July 2006 (No. 7)
• Feature - Pfizer Should Pay Pharmacists to Counsel Patients about Exubera
• Sesquicentennial
• New Drug Review: Insulin glulisine (Apidra)

August 2006 (No. 8)
• Feature - When Price Controls are Established for Drugs, Big Pharma will have Only Itself to Blame
• A Positive Step
• New Drug Review: Rasagiline mesylate (Azilect)

September 2006 (No. 9)
• Feature - September 11
• New Drug Review: Darunavir (Prezista)

October 2006 (No. 10)
• Feature - Wal-Mart's Generics Scam Ignores the Professional Role of Its Pharmacists
• It is Almost Election Day! Do You Know What Your Candidates Stand For?
• New Drug Review: Ranolazine (Ranexa)

November 2006 (No. 11)
• Feature - No More Excuses! Let's Get Cigarettes Out Of Pharmacies!
• Paying $155 Million Means Never Having to Say You are Sorry (or Admit to any Wrongdoing)
• New Drug Review: Sitagliptin phosphate (Januvia)

December 2006 (No. 12)
• Feature - A Christmas Letter
• A Gift of Life
• New Drug Review: Telbivudine (Tyzeka)

Index for
Volume 2, 2007

January 2007 (No. 1)
• Feature - A New Year, an Old Theme
• New Drug Review: Paliperidone (Invega)
• Editor's Note

February 2007 (No. 2
• Feature - Ten Thousand and One Pfizer Employees Lose Jobs – But the "One" is Very Different!
• Editor's Note
• The Gettysburg Address
• New Drug Review 1: Posaconazole (Noxafil)
• New Drug Review 2: Ranibizumab (Lucentis)

March 2007 (No. 3)
• Feature - Pharmacy Must Demand Fair and Immediate Payment for Medications and Services!
• New Drug Review: Aliskiren hemifumarate (Tekturna)
• The Angiotensin-Converting Enzyme Inhibitors (ACEIs)
• The Angiotensin II Receptor Blockers (ARBs)

April 2007 (No. 4)
• Feature - The 20/20 Report on Pharmacy Errors – An Indictment of Some Chain Pharmacies
• The Right Way to Practice Pharmacy
• New Drug Review: Lisdexamfetamine dimesylate (Vyvanse)

May 2007 (No. 5)
• Feature - Pharmacy Errors: Part 2 "More Prescriptions Faster" Policies of Some Chain Pharmacies Increase the Risk of Errors
• New Drug Review: Retapamulin (Altabax)

June 2007 (No. 6)
• Feature - If CMS and AMP do not Turn Pharmacists into Activists, What Will?
• New Drug Review: Rotigotine (Neupro)

July 2007 (No. 7)
• Feature - The Assault on Compounding Must be Rejected!
• New Drug Review: Bismuth subcitrate potassium (Pylera [with metronidazole and tetracycline])

August 2007 (No. 8)
• Feature - Let Your Conscience be Your Guide! (but some pharmacists are being denied this right)
• New Drug Review: Levocetirizine dihydrochloride (Xyzal)

September 2007 (No. 9)
• Feature - Save the Independent Pharmacists!
• New Drug Review: Maraviroc (Selzentry)

October 2007 (No. 10)
• Feature - Behind-the-Counter (BTC) – Long Overdue but, Let's Seize the Day!
• New Drug Review: Raltegravir (Isentress)

November 2007 (No. 11)
• Feature - More Profits or More Blindness? Genentech Should Rescind its Action Against Compounding Pharmacies!
• New Drug Review: Lapatinib (Tykerb)

December 2007 (No. 12)
• Feature - We are Blessed! To Whom Much is Given...
• Editor's Note
• New therapeutic agents marketed in the United States in 2007

Index for
Volume 3, 2008

January 2008 (No. 1)
• Feature - HAPPY NEW YEAR! Resolutions for Our Profession
• New Drug Review: Nebivolol hydrochloride (Bystolic)

February 2008 (No. 2)
• Feature - Medication Errors (Again) – We Must be More Accountable!
• New Drug Review: Etravirine (Intelence)

March 2008 (No. 3)
• Feature - The Chaos of Prescription Drug Benefit Programs
• New Drug Review: Ciclesonide (Omnaris)

April 2008 (No. 4)
• Feature - Health Insurance Threatens the Quality of Health Care!
• New Drug Review: Desvenlafaxine succinate (Pristiq)

May 2008 (No. 5)
• Feature - Consumer Reports' Readers Rate Independent Pharmacies as the Best (but Some Opportunities are Being Missed)
• Neat Mistakes
• New Drug Review: Certolizumab pegol (Cimzia)

June 2008 (No. 6)
• Feature - A Mail-Order Myth
• New Drug Review: Sinecatechins (Veregen)

July 2008 (No. 7)
• Feature - Concern for Patients or Protection of Profits? Legislation Regarding Generic Antiepileptic Drugs is Not Needed!
• Synergies from Working Together
• New Drug Review: Methylnaltrexone bromide (Relistor)

August 2008 (No. 8)
• Feature - 2015 – When the Shortage of Pharmacists Becomes a Surplus! (Unless Major Changes Occur in the Practice of Pharmacy Very Soon)
• New Drug Review: Alvimopan (Entereg)

September 2008 (No. 9)
• Feature - North Dakota has it Right! Challenges to its Pharmacy Ownership Law must be Rejected!
• APHA's Executive Search
• New Drug Review: Sapropterin dihydrochloride (Kuvan)

October 2008 (No. 10)
• Feature - January 1, 2010 – Make This Date the Goal to Get Cigarettes Out of All Pharmacies!
• New Drug Review: Difluprednate (Durezol)

November 2008 (No. 11)
• Feature - The Health Care Pretenders – Health Insurance Companies Should Stick to Providing Insurance and Not Attempt to be Health Care Providers
• New Drug Review: Tetrabenazine (Xenazine)

December 2008 (No. 12)
• Feature - Editorial Updates and Perspectives
• Editor's Note
• New therapeutic agents marketed in the United States in 2008

Index for
Volume 4, 2009

January 2009 (No. 1)
• Feature - A New Year, an Old Theme Can our National Pharmacy Associations Reach Nome?
• New Drug Review: Fesoterodine fumarate (Toviaz)

February 2009 (No. 2)
• Feature - Pfizer Should Not be Permitted to Acquire Wyeth!
• New Drug Review: Milnacipran hydrochloride (Savella)

March 2009 (No. 3)
• Feature - Coupons, $4 generics, and Free Generic Antibiotics – Disservices to Patients and Insults to Pharmacists
• New Drug Review: Silodosin (Rapaflo)

April 2009 (No. 4)
• Feature - Dear Legislator
• New Drug Review: Febuxostat (Uloric)

May 2009 (No. 5)
• Feature - CVS Caremark – An Alliance that Must be Broken
• New Drug Review: Golimumab (Simponi)

June 2009 (No. 6)
• Feature - Prescription Benefit Programs – A New Model is Needed!
• New Drug Review: Besifloxacin hydrochloride (Besivance)

July 2009 (No. 7)
• Feature - The Acetaminophen Challenge (and Recommendations)
• New Drug Review: Lacosamide (Vimpat)

August 2009 (No. 8)
• Feature - Addiction – Pharmacy Should Assume a Leadership Role in Addressing this Devastating Problem!
• New Drug Review: Tapentadol hydrochloride (Nucynta) Analgesic

September 2009 (No. 9)
• Feature - Prescription Benefit Programs – Classes of Pharmacies Should be Established
• New Drug Review: Prasugrel hydrochloride (Effient)

October 2009 (No. 10)
• Feature - The Influenza Follies
• New Drug Review: Saxagliptin hydrochloride (Onglyza)

November 2009 (No. 11)
• Feature - What are they Doing to our Profession? – And Who Cares?
• New Drug Review: Dronedarone (Multaq)

December 2009 (No. 12)
• Feature - No Vacancy
• Congratulations and Appreciation!
• Editor's Note
• New therapeutic agents marketed in the United States in 2009
• The Top 10 New Drugs of the Decade (Millenium)

Index for
Volume 5, 2010

January 2010 (No. 1)
• Feature - Health Care Reform – Let's Start Over and Do It Right!
• New Drug Review: Asenapine (Saphris)

February 2010 (No. 2)
• Feature - Dispensing Error – And a Pharmacist in Prison
• New Drug Review: Iloperidone (Fanapt)

March 2010 (No. 3)
• Feature - Tobacco Sales in Pharmacies – A Historic Decision by APhA Delegates
• New Drug Review: Ustekinumab (Stelara)

April 2010 (No. 4)
• Feature - Pharmacy Must Develop Opportunities Now! (Before Health Insurance "Reform" Limits our Role)
• New Drug Review: Liraglutide (Victoza)

May 2010 (No. 5)
• Feature - Herb Denenberg – The Ultimate Activist and a Great Friend of Pharmacy
• New Drug Review: Dalfampridine (Ampyra)

June 2010 (No. 6)
• Feature - CVS Caremark's Participation in Medicare Prescription Programs should be Terminated!
• New Drug Review: Pitavastatin calcium (Livalo)

July 2010 (No. 7)
• Feature - We Have TOO MANY Colleges of Pharmacy!
• New Drug Review: Denosumab (Prolia)

August 2010 (No. 8)
• Feature - Who are Pharmacy's Leaders?
• New Drug Review: Tocilizumab (Actemra)

September 2010 (No. 9)
• Feature - CARE is Missing in Health Insurance Reform! Independent Pharmacists are Well Positioned to Provide It!
• New Drug Review: Dienogest/estradiol valerate (Natazia)

October 2010 (No. 10)
• Feature - Prescription Benefit Programs – Pharmacy Needs Greater Strength and New Strategies!
• New Drug Review: Polidocanol (Asclera)

November 2010 (No. 11)
• Feature - Strike 3 – CVS Should be OUT!
• New Drug Review: Dabigatran etexilate mesylate (Pradaxa)

December 2010 (No. 12)
• Appreciation and Anticipation
• New Therapeutic Agents Marketed in the United States in 2010
• Index for 2006 – 2010

[To Top]